{"product_id":"global-licensing-partnering-terms-agreements-in-pharma-biotech-diagnostics-2016-2023","title":"Global Licensing Partnering Terms \u0026 Agreements in Pharma, Biotech \u0026 Diagnostics 2016-2023","description":"\u003cp\u003eGlobal Licensing Partnering Terms \u0026amp; Agreements in Pharma, Biotech \u0026amp; Diagnostics 2016-2023\u003c\/p\u003e\n\n\u003cp\u003eThe Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016 - 2023 report provides comprehensive understanding and unprecedented access to the licensing deals and agreements entered into by the worlds leading life science companies.\u003cbr\u003e\n \u003cbr\u003e\nThis report provides details of the latest licensing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date, the report provides details of licensing agreements from 2016 to 2023.\u003cbr\u003e\n \u003cbr\u003e\nThere has been a long standing willingness for parties to enter licensing deals. Such deals enable both parties to benefit from the upside of a big R\u0026amp;D win, whilst mitigating the risks of going it alone in the risky preclinical and clinical development stages.\u003cbr\u003e\n \u003cbr\u003e\nLicensing is a specific type of partnering deal whereby the parties to the deal agree to commercialize a compound, product or technology.\u003cbr\u003e\n \u003cbr\u003e\nSpecifically, licensing is the granting of permission to use intellectual property rights, such as trademarks, patents, or technology, under defined conditions\u003cbr\u003e\n \u003cbr\u003e\nThere are several forms of licensing deal. Traditional licensing arrangement whereby an owner of intellectual property (the licensor) provides access to its technology to another company (the licensee) in return for agreed payments and royalties on subsequent sales of product(s) derived from the intellectual property.\u003cbr\u003e\n \u003cbr\u003e\nIn more recent times, licensing is often the outcome of a successful period of collaboration on the research and development of a technology or compound, resulting in a product which can be commercialized. In this situation, the licensing agreement governs who has permission to commercialize and what payments are due should commercialization proceed.\u003cbr\u003e\n \u003cbr\u003e\nOther forms of licensing such as sub-licensing and cross-licensing are also explored, with examples provided together with listing of recent deals in pharma, biotech and diagnostics.\u003cbr\u003e\n \u003cbr\u003e\nThe report provides a detailed understand and analysis of how and why companies enter licensing deals. The majority of deals are multicomponent whereby the licensee retains either a right or option to license to commercialize the resultant product of the research collaboration. There are also numerous pure licensing deals whereby the products originator takes on a development\/commercialization partner in order to maximize a technologies\/products prospects.\u003cbr\u003e\n \u003cbr\u003e\nUnderstanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.\u003cbr\u003e\n \u003cbr\u003e\nThis report contains a comprehensive listing of all licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.\u003cbr\u003e\n \u003cbr\u003e\nContract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.\u003cbr\u003e\n \u003cbr\u003e\nThe initial chapters of this report provide an orientation of licensing deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in licensing as well as a discussion on the merits of the type of deal.\u003cbr\u003e\n \u003cbr\u003e\nChapter 3 provides an overview of the structure of licensing deals. The chapter includes numerous case studies to enable understanding of both pure licensing deals and multicomponent deals where collaborative R\u0026amp;D forms a part.\u003cbr\u003e\n \u003cbr\u003e\nChapter 4 provides a review of the leading licensing deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.\u003cbr\u003e\n \u003cbr\u003e\nChapter 5 provides a review of the top 25 most active biopharma companies in licensing. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.\u003cbr\u003e\n \u003cbr\u003e\nChapter 6 provides a comprehensive review of licensing financials for deals announced since 2016, including headline value, upfront, milestone payments and royalty rates, providing both benchmark data and access to individual deal financials.\u003cbr\u003e\n \u003cbr\u003e\nChapter 7 provides a comprehensive and detailed review of licensing deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.\u003cbr\u003e\n \u003cbr\u003e\nThe report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J\u0026amp;J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.\u003cbr\u003e\n \u003cbr\u003e\nThe report also includes numerous table and figures that illustrate the trends and activities in licensing deal making since 2016.\u003cbr\u003e\n \u003cbr\u003e\nIn addition, a comprehensive appendix is provided organized by licensing company A-Z , stage of development, therapeutic target, technology type and deal type definitions. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.\u003cbr\u003e\n \u003cbr\u003e\nIn conclusion, this report provides everything a prospective dealmaker needs to know about licensing partnering in the research, development and commercialization of technologies and products.\u003cbr\u003e\n \u003cbr\u003e\nKey benefits\u003cbr\u003e\n \u003cbr\u003e\nGlobal Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 provides the reader with the following key benefits:\u003cbr\u003e\n \u003cbr\u003e\nIn-depth understanding of licensing partnering deal trends since 2016\u003cbr\u003e\nAnalysis of the structure of licensing agreements with real life case studies\u003cbr\u003e\nComprehensive listing of over 5,500 licensing deals since 2016, together with deal terms, value and press release\u003cbr\u003e\nComprehensive access to actual licensing contracts entered into by the world’s life science companies\u003cbr\u003e\nAnalysis of key deal financials including headline value, upfront, milestone payments and royalty rates\u003cbr\u003e\nInsight into the terms included in a licensing agreement, together with real world clause examples\u003cbr\u003e\nUnderstand the key deal terms companies have agreed in previous deals           \u003cbr\u003e\nUndertake due diligence to assess suitability of your proposed deal terms for partner companies\u003cbr\u003e\n \u003cbr\u003e\nReport scope\u003cbr\u003e\n \u003cbr\u003e\nGlobal Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016- 2023 is intended to provide the reader with an in-depth understanding of the licensing trends and structure of deals entered into by leading life science companies worldwide.        \u003cbr\u003e\n \u003cbr\u003e\nGlobal Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016 - 2023 includes:\u003cbr\u003e\n \u003cbr\u003e\nTrends in licensing dealmaking in the biopharma industry since 2016\u003cbr\u003e\nAnalysis of licensing deal structure with case studies of real-life licensing deals\u003cbr\u003e\nComprehensive listing of over 5,500 licensing deals since 2016\u003cbr\u003e\nAccess to licensing contract documents\u003cbr\u003e\nKey financial bnchmarks for headline, upfront, milestone and royalty rates\u003cbr\u003e\nThe leading licensing deals by value since 2016\u003cbr\u003e\nMost active licensing dealmakers since 2016\u003cbr\u003e\nThe leading licensing partnering resources\u003cbr\u003e\n \u003cbr\u003e\nIn Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 available deals and contracts are listed by:\u003cbr\u003e\n \u003cbr\u003e\nCompany A-Z\u003cbr\u003e\nHeadline value\u003cbr\u003e\nTherapeutic area\u003cbr\u003e\nTechnology type\u003cbr\u003e\n \u003cbr\u003e\nEach deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.\u003cbr\u003e\n \u003cbr\u003e\nThe Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 report provides comprehensive access to available contract documents for licensing deals. Analyzing actual contract agreements allows assessment of the following:\u003cbr\u003e\n \u003cbr\u003e\nWhat are the precise rights granted or optioned?\u003cbr\u003e\nWhat is actually granted by the agreement to the partner company?\u003cbr\u003e\nWhat exclusivity is granted?\u003cbr\u003e\nWhat is the payment structure for the deal?\u003cbr\u003e\nHow do milestone align with clinical stage development phases?\u003cbr\u003e\nHow are sales and payments audited?\u003cbr\u003e\nWhat is the deal term?\u003cbr\u003e\nHow are the key terms of the agreement defined?\u003cbr\u003e\nHow are IPRs handled and owned?\u003cbr\u003e\nWho is responsible for commercialization?\u003cbr\u003e\nWho is responsible for development, supply, and manufacture?\u003cbr\u003e\nHow is confidentiality and publication managed?\u003cbr\u003e\nHow are disputes to be resolved?\u003cbr\u003e\nUnder what conditions can the deal be terminated?\u003cbr\u003e\nWhat happens when there is a change of ownership?\u003cbr\u003e\nWhat sublicensing and subcontracting provisions have been agreed?\u003cbr\u003e\nWhich boilerplate clauses does the company insist upon?\u003cbr\u003e\nWhich boilerplate clauses appear to differ from partner to partner or deal type to deal type?\u003cbr\u003e\nWhich jurisdiction does the company insist upon for agreement law?\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"April, 2023 \/ 2800 Pages \/ MCW16229076","offer_id":47646911824178,"sku":null,"price":4794.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-licensing-partnering-terms-agreements-in-pharma-biotech-diagnostics-2016-2023","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}